Literature DB >> 24746197

The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

Ming-Hui Ao1, Hui Zhang1, Lynne Sakowski1, Rajni Sharma1, Peter B Illei1, Edward Gabrielson1, Frederic Askin1, Qing Kay Li2.   

Abstract

In lung cancer, targeted therapies depend on accurate histological subclassification of the tumor. The majority of lung cancers can be subclassified based on hematoxylin and eosin staining; however, classification may be difficult in small biopsies. In this study, we investigated the utility of a newly developed triple marker (combination of TTF1/Napsin A/p40) and compared the sensitivity and specificity of this novel marker with individual markers in the subclassification of non-small cell lung carcinomas. Lung cancer tissue microarrays were constructed using surgical resection material from the Johns Hopkins Hospital. They included 77 adenocarcinomas (ADCs), 77 squamous cell carcinomas (SqCCs), and 46 cases of metastatic lung ADCs. Immunostaining patterns of all markers were scored semi-quantitatively and compared. In ADCs, the sensitivity and specificity of the triple marker were 93.5% and 77.5%, respectively. The sensitivity and specificity of TTF1 and Napsin A were 85.7% and 75.0%, and 89.6% and 90.0%. In SqCCs, the sensitivity and specificity of the triple marker were 88.3% and 92.5%, while the p40, p63 and CK5/6 showed 80.5% and 90.0%; 93.5% and 80.0%; and 89.6% and 80.0%. In addition, the sensitivity and specificity of the triple marker in metastatic ADCs showed 71.7% and 73.5%, respectively. Our triple marker (combination of TTF1/Napsin A/p40) showed a similar sensitivity and specificity for the subclassification of NSCLC when compared to individual markers. Our study not only demonstrates a useful combination of immunomarkers but also optimally conserves tissue for molecular marker testing.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunohistochemical markers; Napsin A; Non–small cell lung carcinoma (NSCLC); Novel triple stain marker; P40

Mesh:

Substances:

Year:  2014        PMID: 24746197      PMCID: PMC4178947          DOI: 10.1016/j.humpath.2014.01.005

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  32 in total

Review 1.  Application of glycoproteomics for the discovery of biomarkers in lung cancer.

Authors:  Qing Kay Li; Edward Gabrielson; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2012-06       Impact factor: 3.494

2.  TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks.

Authors:  Nazneen Fatima; Cynthia Cohen; Diane Lawson; Momin T Siddiqui
Journal:  Cancer Cytopathol       Date:  2011-02-01       Impact factor: 5.284

Review 3.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

4.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

5.  Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

Authors:  Natasha Rekhtman; Daphne C Ang; Camelia S Sima; William D Travis; Andre L Moreira
Journal:  Mod Pathol       Date:  2011-05-27       Impact factor: 7.842

Review 6.  Novel therapeutic targets in non-small cell lung cancer.

Authors:  Filip Janku; Ignacio Garrido-Laguna; Lubos B Petruzelka; David J Stewart; Razelle Kurzrock
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

7.  KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma.

Authors:  Qing Kay Li; Anju Singh; Shyam Biswal; Frederic Askin; Edward Gabrielson
Journal:  J Hum Genet       Date:  2011-01-20       Impact factor: 3.172

8.  Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.

Authors:  Delicia Munfus-McCray; Min Cui; Zhen Zhang; Edward Gabrielson; Frederic Askin; Qing Kay Li
Journal:  Hum Pathol       Date:  2013-01-18       Impact factor: 3.466

9.  A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.

Authors:  Brian Z Ring; Robert S Seitz; Rodney A Beck; William J Shasteen; Alex Soltermann; Stefanie Arbogast; Francisco Robert; Marshall T Schreeder; Douglas T Ross
Journal:  Mod Pathol       Date:  2009-05-08       Impact factor: 7.842

10.  Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.

Authors:  William Sterlacci; Spasenija Savic; Thomas Schmid; Wilhelm Oberaigner; Jutta Auberger; Michael Fiegl; Alexandar Tzankov
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

View more
  18 in total

Review 1.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Authors:  Lais Osmani; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Semin Cancer Biol       Date:  2017-11-26       Impact factor: 15.707

2.  The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.

Authors:  Nehad M R Abd El-Maqsoud; Ehab Rifat Tawfiek; Ayman Abdelmeged; Mohamed Fathy Abdel Rahman; Alaa A E Moustafa
Journal:  Tumour Biol       Date:  2015-10-01

3.  The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.

Authors:  Yunfan Ma; Mengying Fan; Liang Dai; Xiaozheng Kang; Yiqiang Liu; Yu Sun; Wanpu Yan; Zhen Liang; Hongchao Xiong; Keneng Chen
Journal:  Tumour Biol       Date:  2015-05-16

4.  Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.

Authors:  Thomas J Gniadek; Qing Kay Li; Ellen Tully; Samit Chatterjee; Sridhar Nimmagadda; Edward Gabrielson
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

5.  Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinoma.

Authors:  Cheng Zhan; Li Yan; Lin Wang; Yang Sun; Xingxing Wang; Zongwu Lin; Yongxing Zhang; Yu Shi; Wei Jiang; Qun Wang
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

6.  Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations.

Authors:  Mohammed T Lilo; Derek Allison; Yuting Wang; MingHui Ao; Edward Gabrielson; Susan Geddes; Hui Zhang; Frederic Askin; Qing Kay Li
Journal:  J Am Soc Cytopathol       Date:  2016 May-Jun

7.  Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.

Authors:  Peng Cao; Sanlan Wu; Wei Guo; Qilin Zhang; Weijing Gong; Qiang Li; Rui Zhang; Xiaorong Dong; Shuangbing Xu; Yani Liu; Shaojun Shi; Yifei Huang; Yu Zhang
Journal:  Metabolomics       Date:  2021-11-03       Impact factor: 4.290

8.  Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.

Authors:  Grzegorz T Gurda; Lei Zhang; Yuting Wang; Li Chen; Susan Geddes; William C Cho; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Clin Transl Med       Date:  2015-04-21

9.  p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.

Authors:  Ritika Walia; Deepali Jain; Karan Madan; Mehar C Sharma; Sandeep R Mathur; Anant Mohan; Venkateswaran K Iyer; Lalit Kumar
Journal:  Indian J Med Res       Date:  2017-07       Impact factor: 2.375

10.  Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.

Authors:  Joe W Chen; Joseph Dhahbi
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.